Skip to main content
Top
Literature
1.
go back to reference Ethuin F, Boudaoud S, Leblanc I, Troje C, Marie O, Levron JC, Le Moing JP, Assoune P, Eurin B, Jacob L (2003) Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. Intensive Care Med 29:1916–1920CrossRefPubMed Ethuin F, Boudaoud S, Leblanc I, Troje C, Marie O, Levron JC, Le Moing JP, Assoune P, Eurin B, Jacob L (2003) Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. Intensive Care Med 29:1916–1920CrossRefPubMed
2.
go back to reference Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M (1996) Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82:167–72PubMed Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M (1996) Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82:167–72PubMed
3.
go back to reference Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222–239PubMed Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222–239PubMed
4.
go back to reference Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, Raisys V, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL (1994) Use of midazolam as a human cytochrome P450 3A probe. I. In vitro–in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549–556 Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, Raisys V, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL (1994) Use of midazolam as a human cytochrome P450 3A probe. I. In vitro–in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549–556
5.
go back to reference Xie CX, Piecoro LT, Wermeling DP (1997) Gender-related considerations in clinical pharmacology and drug therapeutics. Crit Care Nurs Clin N Am 9:459–468 Xie CX, Piecoro LT, Wermeling DP (1997) Gender-related considerations in clinical pharmacology and drug therapeutics. Crit Care Nurs Clin N Am 9:459–468
6.
go back to reference Jones DR, Gorski JC, Haehner BD, O’Mara EM, Hall SD (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374–384PubMed Jones DR, Gorski JC, Haehner BD, O’Mara EM, Hall SD (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374–384PubMed
7.
go back to reference Monk JP, Beresford R, Ward A (1988) Sufentanil: a review of its pharmacological properties and therapeutic use. Drugs 36:286–313PubMed Monk JP, Beresford R, Ward A (1988) Sufentanil: a review of its pharmacological properties and therapeutic use. Drugs 36:286–313PubMed
8.
go back to reference Kvietys PR, Granger DN (1982) Vasoactive agents and splanchnic oxygen uptake. Am J Physiol 243:G1–G9PubMed Kvietys PR, Granger DN (1982) Vasoactive agents and splanchnic oxygen uptake. Am J Physiol 243:G1–G9PubMed
Metadata
Title
Sufentanil in the ICU setting
Authors
Jordan Kountchev
Romuald Bellmann
Michael Joannidis
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 6/2004
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-004-2224-6

Other articles of this Issue 6/2004

Intensive Care Medicine 6/2004 Go to the issue